Albany Molecular Research (AMRI) : Obermeyer Wood Investment Counsel Lllp scooped up 39,893 additional shares in Albany Molecular Research during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 1,788,043 shares of Albany Molecular Research which is valued at $25,604,776.Albany Molecular Research makes up approximately 2.43% of Obermeyer Wood Investment Counsel Lllp’s portfolio.
Other Hedge Funds, Including , American Capital Management Inc boosted its stake in AMRI in the latest quarter, The investment management firm added 32,730 additional shares and now holds a total of 1,336,230 shares of Albany Molecular Research which is valued at $19,134,814. Albany Molecular Research makes up approx 1.53% of American Capital Management Inc’s portfolio.Palisade Capital Managementnj reduced its stake in AMRI by selling 30,721 shares or 4.36% in the most recent quarter. The Hedge Fund company now holds 673,629 shares of AMRI which is valued at $9,646,367. Albany Molecular Research makes up approx 0.41% of Palisade Capital Managementnj’s portfolio.Simplex Trading reduced its stake in AMRI by selling 1,044 shares or 62.67% in the most recent quarter. The Hedge Fund company now holds 622 shares of AMRI which is valued at $9,094.Franklin Street Advisors Inc Nc reduced its stake in AMRI by selling 18,775 shares or 18.14% in the most recent quarter. The Hedge Fund company now holds 84,750 shares of AMRI which is valued at $1,214,468. Albany Molecular Research makes up approx 0.22% of Franklin Street Advisors Inc Nc’s portfolio.
Albany Molecular Research opened for trading at $15.37 and hit $15.46 on the upside on Monday, eventually ending the session at $15.4, with a gain of 0.59% or 0.09 points. The heightened volatility saw the trading volume jump to 4,04,105 shares. Company has a market cap of $550 M.
Albany Molecular Research Inc. is a global contract research and manufacturing organization providing drug discovery development and manufacturing services. The Company operates in three business segments: Discovery and Development Services (DDS) API and Drug Product. The Company offers a portfolio of services from target identification tools to investigational new drug (IND) enabling activities. The Company’s manufacturing facilities are situated in various locations in the United States Europe and Asia. The Company provides state-of-the-art facilities and solutions to deliver integrated pharmaceutical drug development programs and services including process research and development pre-formulation and formulation development good laboratory practices (GLP) bioanalytical and separation sciences.